



BioLineRx to Present at the Annual ROTH Growth Stock Conference in California

March 5, 2014

JERUSALEM--(BUSINESS WIRE)--Mar. 5, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.

The BioLineRx presentation is scheduled to start at 09:30 a.m. PST (12:30 p.m. EST) on Monday, March 10, 2014. A live audio webcast of the presentation will be available online at [BioLineRx's investor web page](#). An archive of the event will also be available for those unable to listen live.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which recently commenced a Phase 1/2 study.

For more information on BioLineRx, please visit www.bioglinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Source: BioLineRx

[Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D., 212-375-2664

jdrumm@tiberend.com

or

Andrew Mielach, 212-375-2694

amielach@tiberend.com

Or

Tsippi Haitovsky, +972-3-6240871

Public Relations

tsipih@netvision.net.il